Multidimensional LC-MS/MS Enables simultaneous quantification of intact human insulin and five recombinant analogs in human plasma

Analytical Chemistry

Volumn 86, Issue 1, 2014, Pages 694-702

  Chambers, Erin E ^a   Fountain, Kenneth J ^b   Smith, Norman ^a   Ashraf, Leah ^a   Karalliedde, Janaka ^a   Cowan, David ^a   Legido Quigley, Cristina ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b WATERS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURATE QUANTIFICATIONS; ANION-EXCHANGE STATIONARY PHASE; BOVINE INSULIN; DIABETIC PATIENT; FORENSIC TOXICOLOGY; INTRA-DAY ACCURACY; PARTICLE COLUMN; SELECTIVITY AND SENSITIVITY;

NEGATIVE IONS; PLASMA (HUMAN);

INSULIN;

DRUG DERIVATIVE; INSULIN;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BLOOD; CATTLE; GENETICS; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METHODOLOGY; MOLECULAR GENETICS; TANDEM MASS SPECTROMETRY;

AMINO ACID SEQUENCE; ANIMALS; CATTLE; CHROMATOGRAPHY, LIQUID; HUMANS; INSULIN; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; TANDEM MASS SPECTROMETRY;

EID: 84891756017     PISSN: 00032700     EISSN: 15206882     Source Type: Journal    
DOI: 10.1021/ac403055d     Document Type: Article

References (41)

1. International Diabetes Federation. IDF Diabetes Atlas, 6thed., (2013. www.diabetesatlas.org/content/diabetes-and-impaired-glucose-tolerance.
2. Krein, S. L.; Vijan, S.; Choe, H. M.; Hayward, R. A. J. Am. Med. Assoc. 2006) 296, 2680
3. ThinkBiotech, LLC. DrugPatentWatch, (2013. www.drugpatentwatch.com.
4. Cai, X.-Y.; Wake, A.; Gouty, D. Bioanalysis 2013) 5, 517-520
5. World Anti-Doping Agency, (2013. http://www.wada-ama.org/.
6. Marks, V. Drug Test. Anal. 2009) 1, 162-176
7. Chambers, E. E.; Legido-Quigley, C.; Smith, N.; Fountain, K. J. Bioanalysis 2012, 5, 65-81
8. Chen, Z.; Caulfield, M. P.; McPhaul, M. J.; Reitz, R. E.; Taylor, S. W.; Clarke, N. J. Clin. Chem. 2013, in press
9. Hess, C.; Thomas, A.; Thevis, M.; Stratmann, B.; Quester, W.; Tschoepe, D.; Madea, B.; Musshoff, F. Anal. Bioanal. Chem. 2012, 404, 1813-1822
10. Thevis, M.; Thomas, A.; Schänzer, W. Mass Spectrom. Rev. 2008, 27, 35-50
11. Jones, A. R.; Carroll, K.; Knight, D.; MacLellan, K.; Domann, P. J.; Legido-Quigley, C.; Huang, L. H.; Smallshaw, L.; Mirzaei, H.; Shofstahl, J.; Paton, N. W. Nat. Biotechnol. 2010, 28, 654-654
12. Thevis, M.; Thomas, A.; Delahaut, P.; Bosseloir, A.; Schänzer, W. Anal. Chem. 2006, 78, 1897-1903
13. Thevis, M.; Thomas, A.; Schänzer, W.; Östman, P.; Ojanperä, I. Drug Test. Anal. 2012, 4, 53-56
14. Thomas, A.; Schänzer, W.; Delahaut, P.; Thevis, M. Drug Test. Anal. 2009, 1, 219-227
15. Thomas, A.; Schänzer, W.; Delahaut, P.; Thevis, M. Methods 2012, 56, 230-235
16. Thomas, A.; Thevis, M.; Delahaut, P.; Bosseloir, A.; Schänzer, W. Anal. Chem. 2007, 79, 2518-2524
17. Blackburn, M.; Bell, B.; Gray, N.; Schmidt, R.; Schmidt, D.; McDougall, S. Presented at the European Bioanalytical Forum 5th Open Meeting, Barcelona, Spain, 2012.
18. Kelley, M.; Ahene, A.; Gorovts, B.; Kamerud, J.; King, L.; McIntosh, T.; Yang, J. AAPS J. 2013, 15, 646-658
19. Issaq, H. J.; Chan, K. C.; Janini, G. M.; Conrads, T. P.; Veenstra, T. D. J. Chromatogr., B 2005, 817, 35-47
20. Ismaiel, O. A.; Zhang, T.; Jenkins, R.; Karnes, H. T. J. Chromatogr., B 2011, 879, 2081-2088
21. Rogatsky, E.; Balent, B.; Goswami, G.; Tomuta, V.; Jayatillake, H.; Cruikshank, G.; Vele, L.; Stein, D. T. Clin. Chem. 2006, 52, 872-879
22. Liu, A.; Tweed, J.; Wujcik, C. E. J. Chromatogr., B 2009, 877, 1873-1881
23. European Medicines Agency. Summary of Product Characteristics, (2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000528/WC500036662.pdf.
24. Karalliedde, J.; Smith, A.; DeAngelis, L.; Mirenda, V.; Kandra, A.; Botha, J.; Ferber, P.; Viberti, G. Hypertension 2008) 51, 1617-1623
25. Dessapt, C.; Karalliedde, J.; Hernandez-Fuentes, M.; Martin, M. P.; Maltese, G.; Dattani, N.; Atkar, R.; Viberti, G.; Gnudi, L. Diabetes Care 2010, 33, 875-877
26. Ewles, M.; Goodwin, L. Bioanalysis 2011, 3, 1379-1397
27. Lepore, M.; Pampanelli, S.; Fanelli, C.; Porcellati, F.; Bartocci, L.; Di Vincenzo, A.; Cordoni, C.; Costa, E.; Brunetti, P.; Bolli, G. B. Diabetes 2000, 49, 2142-2148
28. Lilly, E. Personal Communication, 2013.
29. Porcellati, F.; Rossetti, P.; Busciantella, N. R.; Marzotti, S.; Lucidi, P.; Luzio, S.; Owens, D. R.; Bolli, G. B.; Fanelli, C. G. Diabetes Care 2007, 30, 2447-2452
30. Porcellati, F.; Rossetti, P.; Ricci, N. B.; Pampanelli, S.; Torlone, E.; Campos, S. H.; Andreoli, A. M.; Bolli, G. B.; Fanelli, C. G. Diabetes Care 2007, 30, 1261-1263
31. Bowsher, R. R.; Nowatzke, W. L. Bioanalysis 2011, 3, 883-98
32. Chambers, E.; Wagrowski-Diehl, D. M.; Lu, Z.; Mazzeo, J. R. J. Chromatogr., B 2007, 852, 22-34
33. World Anti-Doping Agency. TechnicalDocument TD2010MRPL.
34. Kirkland, J. J.; Schuster, S. A.; Johnson, W. L.; Boyes, B. E. J. Pharm. Anal. 2013, in press
35. Wagner, B. M.; Schuster, S. A.; Boyes, B. E.; Kirkland, J. J. J. Chromatogr., A 2012, 1264, 22-30
36. Characterization of Protein Therapeutics Using Mass Spectrometry; Springer: New York, 2013.
37. Gilar, M.; Olivova, P.; Daly, A. E.; Gebler, J. C. J. Sep. Sci. 2005, 28, 1694-1703
38. Bansal, S.; DeStefano, A. AAPS J 2007, 9, E109-E114
39. FDA, Rockville, MD, U.S.A., 2001.
40. Bolli, G. B.; Hahn, A. D.; Schmidt, R.; Eisenblaetter, T.; Dahmen, R.; Heise, T.; Becker, R. H. A. Diabetes Care 2012, 35, 2626-2630
41. Novo Nordisk. NovoLog Mechanism of Action, (2013. http://www.novologpro. com/pharmacology/mechanism-of-action.aspx.